Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Danske Hypotek: Interim Report January - June 2022

First half-year in briefJanuary – June 2022 (comparison with January – June 2020 in parentheses)· Operating profit was SEK 501 million (536 million) · Net interest income amounted to SEK 635 million (668 million) · Costs comprised SEK 127 million (77 million) · Reversals of reservations for credit losses amounted to SEK 16 million, for the corresponding period in 2021 reservations amounted to SEK 39 million. · Return on equity was 11.8 % (14.5 %) · The CET1 capital ratio was 16.3 % (16.0 %) Danske Hypotek’s covered bonds have the highest credit rating (AAA) from Standard

Biosergen completes the third cohort of BSG005 phase I trial

August 26, 2022: Biosergen AB (“Biosergen” or the “Company”) today announced that the Safety Review Committee has decided to continue the trial with cohort 4 in the Single Ascending Dose part of BSG005’s phase I trial.BSG005 is Biosergen’s lead development compound. It is a novel anti-fungal molecule from the group of polyene macrolides known for their broad anti-fungal and fungicidal effect, including on resistant and difficult-to-treat fungal strains, which make them unique within all antifungal drug classes.  The successful completion of the phase I trials will demonstrate, that BSG005

Glaston Oyj Abp - Managers' Transactions

Glaston Corporation     Stock Exchange Release, Managers' Transactions 26.8.2022 at 11.45Glaston Oyj Abp - Managers' Transactions____________________________________________Person subject to the notification requirementName: Veli-Matti ReinikkalaPosition: Member of the Board/Deputy member Issuer: Glaston Oyj AbpLEI: 743700V3I7CLI3DJ8L62Notification type: INITIAL NOTIFICATIONReference number: 18862/7/6____________________________________________ Transaction date: 2022-08-25Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000369657Nature of the

Publication of a Prospectus

26 August 2022 International Personal Finance plc Publication of Prospectus The following prospectus (the "Prospectus") has been approved by the Financial Conduct Authority and is available for viewing: Prospectus dated 25 August 2022 relating to the International Personal Finance plc's €1,000,000,000 Euro Medium Term Note Programme. To view the full document together with the documents incorporated by reference, please paste the following URL into the address bar of your browser: http://www.ipfin.co.uk/en/investors/debt-funding-information.html For further information

Correction of previously issued announcement todat at 09:30 CET "Sivers Semiconductors invites to Capital Markets Day 2022"

Sivers Semiconductors AB issues a correction of press release 2022-08-26 at 09.30 regarding the invitation to Sivers Semiconductors Capital Markets Day in Stockholm. The correct date for the Capital Marlets Day 2022 is Monday 26 September, which has been corrected below. Sivers Semiconductors AB invites institutional investors, financial analysts and the media to a Capital Markets Day in Stockholm on Monday, September 26, 2022.The aim of the day is to increase the understanding of Sivers Semiconductors’ operations and markets after the acquisition of the US company MixComm, which has

Hynion in partnership with PDC Machines

Hynion has selected PDC Machines to supply compressors for their new hydrogen filling stations, which are set to be built in Västerås and Jönköping in Sweden.  These projects require dependable and robust compressors, as they represent a new generation of stations with the capacity to refuel dozens of trucks per day.  Each station will deliver hydrogen at 35 and 70 MPa and will service both light and heavy-duty vehicles.“We see this partnership as the start of an ambitious, long-term collaboration”, says Ulf Hafseld, CEO of Hynion. “Good dialogue, good products and good service are

Eric Johansson and Åsa Fredin moves their ownership in K-Fastigheter to Swedish endowment insurances

Eric Johansson, Head of business area Construction, and Åsa Fredin, Head of business area Project Development at K-Fast Holding AB (publ), have during August 26th, through their respective fully owned companies Aalto Holding AB and Åsa Fredin AB moved their ownership in K-Fastigheter to a respective Swedish endowment insurance. This will be reported in the PDMR transactions register at Finansinspektionen (the Swedish Financial Supervisory Authority). The transfer is only internally in Aalto Holding AB and Åsa Fredin AB whereby Eric Johansson and Åsa Fredins ownership in K-Fastigheter remain

Information from Interim report January-June 2022 Misen Energy AB (publ)

Following is a summary of the financial information given Interim report January - June 2022 (1H 2022) from Misen Energy AB (publ) published today. The complete report is attached and is available in both English and Swedish on the Company's website: https://misenenergy.se/repository/Financial_reports_ENG/Misen_Energy_Q2_2022_ENG.pdf  Results for April-June 2022 (within brackets same period 2021): · Consolidated operating group result KSEK -6,996 (-18,213) · Consolidated group net turnover: KSEK 0 (146) · Earnings per share: SEK -0.05 (-0.12) · Production of natural gas: at

Sivers Semiconductors invites to Capital Markets Day 2022

Sivers Semiconductors AB invites institutional investors, financial analysts and the media to a Capital Markets Day in Stockholm on Thursday, September 26, 2022.The aim of the day is to increase the understanding of Sivers Semiconductors’ operations and markets after the acquisition of the US company MixComm, which has made Sivers Wireless a strong global contender in 5G, SATCOM and radar. The Capital Markets Day will go into the company's unique offer within Sivers Photonics. Presentations will be held by group management as well as by customers and partners. Date: 26 September 2022

Arbitral award passed in Feelgood compulsory redemption proceedings

Terveystalo Plc Press Release 26 August 2022 at 10:30 EEST On 27 July 2021, Terveystalo Plc (“Terveystalo”) announced that its wholly owned subsidiary Terveystalo Healthcare Oy (“Terveystalo Healthcare”) had acquired in aggregate 97.42 percent of the shares and votes in Feelgood Svenska AB (publ) (“Feelgood”) after the completion of the recommended mandatory cash offer to the shareholders of Feelgood to tender all their shares in Feelgood to Terveystalo Healthcare for a consideration of SEK 5.70 (at the time, approximately EUR 0.566) in cash per share. Terveystalo further announced that

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 166 - 26 AUGUST 2022 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 158/22. A/S Motortramp participates in NORDEN’s share buy-back program by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in NORDEN.     Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor

BioStock: Spago Nanomedical on the autumn newsflow

During the second quarter, Lund-based Spago Nanomedical carried out a rights issue securing financial resources to keep up the pace of the development work with Tumorad, the company's radionuclide treatment for cancer. The company's second project, a new contrast agent for MRI diagnostics, is already in clinical trial. BioStock contacted CEO Mats Hansen for an update on the autumn news flow.Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se: https://www.biostock.se/en/2022/08/spago-nanomedical-on-the-autumn-newsflow/ This is a press release from BioStock -

Composition of Kamux’s Shareholders’ Nomination Board

Kamux Corporation, Stock Exchange Release, 26.8.2022 at 10:00 Composition of Kamux’s Shareholders’ Nomination Board The largest shareholders of Kamux Corporation have nominated their representatives for the Shareholders’ Nomination Board for the term 2022–2023. The Shareholders’ Nomination Board consists of four members. The right to appoint members representing the shareholders belongs to the three shareholders whose proportions of the votes of all shares of the Company are the largest, according to the shareholders’ register held by Euroclear Finland Ltd on the first business day

Significant increase in demand for NIB’s financing

During the first six months of 2022, the Bank has seen a significant increase in demand for its financing. NIB agreed a total of EUR 2,203 million in new loans and disbursed EUR 2,142 million, compared to EUR 664 million and EUR 1,266 million respectively in the same period in 2021.The new lending was distributed across different sectors and countries and include sustainability-linked loans and NIB’s first purchase of a bond eligible under the Minimum Requirement for its own funds and Eligible Liabilities (MREL) issued by a financial institution. “In these times, the need for the Nordic

Endomines reports new, high-grade drill results from the Pampalo gold mine

Endomines AB, stock exchange release 26th August 2022 at 09:00 CET   Endomines is pleased to report drill results from the underground core drilling program carried out in the spring/summer 2022 at the Pampalo Gold Mine in Finland. The drill program consisted of fifty tree (53) diamond drill holes for a total of 4 330 m. Drill holes were targeted to the area between the 815 and 875 mine levels, representing the next sixty (60) vertical meters below the current production area.   Highlighted drill results include:   · T-1753 intersected 8.2 meters at 13.1 g/t gold,

RLS GLOBAL AB (PUBL) INTERIM REPORT, Q2, 2022

APRIL 1[st] – JUNE 30[th ](Previous year in brackets) · Net sales amounted to TSEK 397 (TSEK 244). · Earnings before interest and taxes (EBIT) amounted to MSEK -5,8 (MSEK 8,5). · Earning per share before dilution at SEK -0,09 (SEK 0,13). · Cash flow from operating activities amounted to TSEK -5 929 (TSEK -6 280). · Liquid assets at the end of the period MSEK 5,8 (MSEK 6,9). · Equity ratio was 43 % (87 %).  JANUARY 1[st] – JUNE 30[th ](Previous year in brackets) · Net sales amounted to TSEK 705 (TSEK 302). · Earnings before interest and taxes (EBIT) amounted

Enzymatica announces outcome of new rights issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. The Board of Directors for Enzymatica (”Enzymatica” or ”Company”) today announces the outcome of the new rights issue with preferential rights for existing shareholders that was published on 19 July 2022 (the “Rights issue”). The new rights issue was fully subscribed, and the Company will receive proceeds amounting to about SEK 74.7 million before issue

Board member Lars Hedbys takes over as acting CEO of RhoVac on 1 September

RhoVac AB ("RhoVac") announces today, August 26[th] 2022, that the board has decided to appoint board member Lars Hedbys as acting CEO of RhoVac, starting from September 1, 2022. As previously announced, Anders Månsson submitted his resignation on 15 July and will take up his new position on 1 September.Gunnar Gårdemyr, chairman of the board: "As Lars has worked on the board of RhoVac since 2015 and has experience from similar assignments, he is well suited to take over the role of acting CEO at Rhovac during the period until RhoVac's future is decided."

Hamlet Pharma Year-end Report July 2021 – June 2022

Opening remarks The fiscal year 2021/2022 of Hamlet Pharma AB has been very successful and important milestones have been reached. The company has consolidated its financial position by raising significant capital, competed successfully for continued funding from the EU Horizon 2020 program, produced drug for clinical trials on a large scale, conducted successful clinical trials, added brain tumor therapy as a new indication for drug development and progressed with the BAMLET drug candidate.Financing and leadership The year started with the successful completion of a funding round

Klaria Interimreport 1 January–30 June 2022 Q2 2022

Klaria Interimreport 1 January–30 June 2022 Q2 2022Summary of the interim report Second quarter of 2022 - Net sales amounted to 0.0 MSEK (0.0 MSEK) - Other income amounted to 3.7 MSEK (0.0 MSEK) - R&D costs for the period amounted to 14.7 MSEK (11.5 MSEK) - Profit after tax amounted to -14.5 MSEK (15.9 MSEK) - Earnings per share for the quarter amounted to -0.24 SEK (0.31 SEK) - Cash flow from operating activities amounted to -15.7 MSEK (13.5 MSEK) - Cash and cash equivalents on the balance sheet date amounted to 7.3 MSEK (39.7 MSEK) - Equity as of June 30

Viking Line – Strong demand partly offset high energy prices

Viking Line Abp              HALF YEAR FINANCIAL REPORT                 26.08.2022, 9.30 AMHalf Year Financial Report for the period January - June 2022 Viking Line – Strong demand partly offset high energy prices   January–June 2022 (compared to January–June 2021)  · Sales amounted to EUR 199.8 M (EUR 71.5 M). · Other operating revenue was EUR 8.3 M (EUR 33.6 M). · Operating income totalled EUR -8.0 M (EUR 4.5 M). · Net financial items were EUR -4.7 M (EUR -2.4 M). · Income before taxes amounted to EUR -12.7 M (EUR 2.2 M). · Income after taxes totalled EUR -9.

Rejlers signs framework agreement with FMV

Rejlers has signed a framework agreement with FMV (the Swedish Defence Materiel Administration) regarding support and expertise in connection to the supply of fixed and mobile power systems. The framework agreement runs for two years with the possibility of an extension for another two years. The Swedish Armed Forces can also call-off on the agreement.FMV procures, develops and delivers materiel and services to the Swedish Armed Forces. Rejlers has extensive experience in supporting FMV with expertise in several areas of technology. The recently signed framework agreement includes expertise

Truecaller for Business launches new and enhanced capabilities for enterprise customers

Truecaller for Business (“TfB”), Truecallers enterprise offering, is now launching several enhanced features like “Video Caller ID”, “Call Me back-function”, “Call Ratings” and “Surveys”. Improvements have also been made to the platform to be able to onboard new clients faster. The new capabilities significantly strengthen Truecallers current enterprise offering.Truecaller for Business, Truecallers enterprise offering, which was launched late 2020 has since inception onboarded a large spectrum of clients across different sectors in India and other focus markets like South Africa, Egypt,

SkartaNYAB Plc acquires Power Forze AB and arranges a directed share issue

SkartaNYAB PlcCOMPANY ANNOUNCEMENT26 August 2022 at 09:30SkartaNYAB Plc acquires Power Forze AB and arranges a directed share issue SkartaNYAB Plc, builder of a clean future, acquires all shares in a Swedish company Power Forze AB. Purchase price for the shares is 38.5 million SEK, of which 8.5 million SEK will be paid as a cash consideration and the remaining by arranging a directed share issue for Power Forze AB’s shareholders. The acquisition has no significant impact on this year’s revenue and result of SkartaNYAB. 4,006,400 new shares in SkartaNYAB Plc will be issued in the

There are no items matching the current filter
There are no more items matching the current filter
Back to top